VIDEO: Deepak L. Bhatt, MD, MPH, highlights hot topics in cardiometabolic medicine

ByDeepak L. Bhatt, MD, MPH

Fact checked byErik Swain

PHILADELPHIA — In this Healio video exclusive, Deepak L. Bhatt, MD, MPH, discusses two hot topics in cardiometabolic medicine: icosapent ethyl and sotagliflozin.

At the Heart in Diabetes CME Conference, Bhatt presented an overview of the REDUCE-IT trial and new analyses of icosapent ethyl (Vascepa, Amarin), including data from the RESPECT-EPA trial.

Bhatt, a member of the Healio | Cardiology Today Editorial Board, also highlights new data for the SGLT1/SGLT2 inhibitor sotagliflozin (Inpefa, Lexicon), including its benefit in patients with heart failure with or without diabetes, heart failure with preserved or reduced ejection fraction, and in patients with diabetes and chronic kidney disease.

More data will come out in the next few months, Bhatt, who is director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, told Healio.

Reference:

Bhatt DL. Important issues in cardiometabolism. Presented at: Heart in Diabetes CME Conference; June 7-9, 2024; Philadelphia.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Bhatt reports various financial ties to industry, including relationships with Amarin and Lexicon.

Heart in Diabetes

Read more

VIDEO: Deepak L. Bhatt, MD, MPH, highlights hot topics in cardiometabolic medicine

Reference:

Related Content